The 39% adjusted EPS beat and raised guidance reflect strong margin execution and aggressive share repurchases. Watch for closing of the Acute Care/Interventional Urology divestiture by year-end, which would fund the remaining $400M buyback authorization and further reduce share count. The EZPLAZ revenue ramp and Freesolve BIOMAG-II data in late 2027 are longer-term catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $152.15entry
- T+1 · 11d ago −0.84%α −1.15% · $150.87
- T+5 · 5d ago +0.66%α −2.63% · $153.15
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teleflex Q3 2026 revenue of $567.8M was essentially flat YoY (+0.2% reported, +3.0% pro forma adjusted constant currency), while adjusted EPS rose 39% to $2.63, well above the $1.89 consensus. The company raised its full-year adjusted EPS guidance to $7.50-$7.75 from $6.90-$7.20 and maintained its 3.5%-4.5% pro forma revenue growth outlook, citing margin expansion and $350M in share repurchases since July.
Key Financial Metrics
Key Facts
- Q3 2026 revenue from continuing operations $567.8M, up 0.2% YoY reported, up 3.0% pro forma adjusted constant currency
- GAAP diluted EPS from continuing operations $1.30 vs $(1.32) in prior year period
- Adjusted diluted EPS from continuing operations $2.63 vs $1.89 in prior year period, a 39.2% increase
- Adjusted gross margin 66.8% vs 62.3% in prior year; adjusted operating margin 25.0% vs 22.0%
- Full year 2026 adjusted EPS guidance raised to $7.50-$7.75 from $6.90-$7.20
- Pro forma adjusted constant currency revenue growth guidance maintained at 3.5%-4.5%
- Repurchased $350M of common stock since July 1, 2026 through ASR and open-market purchases
- Completed OEM divestiture for $1.5B in cash ($1.25B after-tax) on August 3, 2026
- Received $39.2M in IEEPA tariff refunds during Q3, with $25.3M benefit in continuing operations
- EZPLAZ freeze-dried plasma received FDA BLA approval; potential long-term U.S. market opportunity of at least $200M
- Freesolve resorbable magnesium scaffold received FDA Breakthrough Device Designation for PCI
Financial Impact
Adjusted EPS of $2.63 beat consensus of $1.89 by 39.2%; full-year adjusted EPS guidance raised by $0.60 at midpoint to $7.50-$7.75
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Vascular | $243.5M | +4.7% |
| Interventional | $210.3M | -2.6% |
| Surgical | $114.0M | +4.2% |
Risk Factors
- Acute Care/Interventional Urology divestiture closing may extend into 2027, delaying planned capital returns
- Interventional segment integration remains a work in progress; Q3 pro forma constant currency growth was only 0.2%
- Adjusted operating margin guidance of ~20% includes $16.5M of IEEPA tariff refunds that may not recur
- Activist investor campaign noted in legal fees; ongoing pressure could force strategic changes
- GAAP revenue growth guidance reduced to 13.2%-14.2% due to FX headwinds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000096943-26-000107 |
| Exhibit: ex992to11-5x2026req32026.htm | 0000096943-26-000107 |
| Document: tfx-20261105.htm | 0000096943-26-000107 |
| Document: 0000096943-26-000107-index-headers.html | 0000096943-26-000107 |
| Document: 0000096943-26-000107-index.html | 0000096943-26-000107 |
| Document: 0000096943-26-000107.txt | 0000096943-26-000107 |
| 8-K Data (Synthetic) | 0000096943-26-000107 |
Track record
11 reports on TFX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $154.69 Now $157.10 +1.56% settles Nov 23
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $152.15 to $153.15 Now $157.10 +3.25% ▲ +0.66% −2.63% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $138.89 to $137.37 Now $157.10 +13.11% ▼ −1.09% −2.31% vs SPY
- Jul 2, 202619w ago Court Ruling Bullish 6/10 Entry $133.99 to $134.04 Now $157.10 +17.25% ▲ +0.04% −0.89% vs SPY
- Jun 22, 202621w ago Institutional Cluster Mixed 4/10 Entry $121.67 to $129.86 Now $157.10 +29.12% ▲ +6.73% +8.80% vs SPY
- Jun 15, 202622w ago 8-K Neutral 4/10 Entry $127.87 to $124.26 Now $157.10 +22.86% ▼ −2.82% −0.59% vs SPY
- Jun 9, 202622w ago 8-K Neutral 2/10 Entry $132.15 to $127.87 Now $157.10 +18.88% ▼ −3.24% −6.67% vs SPY
- Jun 1, 202624w ago 8-K Neutral 4/10 Entry $127.31 to $129.84 Now $157.10 +23.40% ▲ +1.98% +4.73% vs SPY
- May 27, 202624w ago 8-K Neutral 4/10 Entry $128.90 to $131.04 Now $157.10 +21.87% ▲ +1.66% +1.34% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Entry $131.59 to $130.04 Now $157.10 +19.38% ▼ −1.18% −2.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers